Cambios en la expresión de los marcadores de disfunción endotelial PAL-1/PAI-2 en preeclampsia leve y severa, y en gestantes normotensas sanas

  • Rodrigo Valenzuela Grau
  • Rodrigo Gutiérrez Rojas
  • Rocio Cardenas De la Torre
  • Jaime González Montero
  • Ramón Rodrigo Salinas
  • Mauro Parra Cordero

Resumen

Objetivo: Determinar las concentraciones del Inhibidor del Activador del Plasminógeno tipo 1 y 2(PAI 1 y 2) y del factor de crecimiento placentario (PIGF)  como marcadores de disfunción endotelial y angiogénesis en preeclampsia(PE) leve y severa, respectivamente. Métodos: Estudio de casos y controles realizado en el Hospital Clínico de la Universidad de Chile durante junio del 2009 y diciembre del 2010. La población estuvo conformada por embarazadas adscritas durante el periodo de estudio y fue dividida en tres grupos: controles (n= 18), PE leve (n=9), PE severa (n=23). Se determinaron las concentraciones de PIGF y PAI-1/PAI-2 mediante técnicas de inmunoensayo a partir de las muestras obtenidas de cada paciente. Para el análisis estadístico se utilizó test de ANOVA-Bonferroni. Se consideró significativo un p < 0.05. Resultados: Se observó niveles menores de PlGF y mayores de PAI-1/PAI-2 en PE en comparación con los controles. Mujeres con PE severa mostraron niveles más altos de relación PAI-1/PAI-2 que mujeres con PE leve (p < 0.05). No hubo diferencia significativa para PlGF entre PE leve y severa. Conclusiones: La gravedad de la preeclampsia podría reflejarse en alteraciones de los biomarcadores de disfunción endotelial y angiogénesis. La medición de PlGF y relación PAI-1/PAI-2 en embarazos tempranos podría tener un valor pronóstico en el desarrollo de PE

Citas

  1. Lewis G et al. Why mother die: Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996. Department of Health, Welsh Office Scotish Office Department of Health and Department of Health and Social Services. London. 1998. Ref Type: Report
  2. Valdes G, Oyarzun E. Síndromes hipertensivos del embarazo. In: Eds A Pérez y E Donoso, editor. Obstetricia.Santiago, Chile: Publicaciones Técnicas Mediterráneo; 1999. p. 52.
  3. Parra-Cordero M, Lees C, Missfelder-Lobos H, Seed P, Harris C. Fetal arterial and venous Doppler pulsatility index and time averaged ranges for a high risk population. Ultrasound in Obstetrics & Gynecology 2007;being reviewed.
  4. Roberts JM. Endothelial dysfunction in preeclampsia. Semin. Reprod. Endocrinol. 1998;16:5-15.
  5. Meis PJ, Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Miodovnik M. The preterm prediction study: risk factors for indicated preterm births. Am.J.Obstet.Gynecol. 1998;178:562-67.
  6. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: current concepts. Am.J.Obstet.Gynecol. 1998;179:1359-75.
  7. Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am. J. Obstet. Gynecol. 1988;158:892-898.
  8. Redman CW: Current topic: pre-eclampsia and the placenta. Placenta 1991, 12:301-308.
  9. Scott JS: Pregnancy toxaemia associated with hydrops foetalis, hydatidiform mole and hydramnios. J Obstet Gynaecol Br Empire 1958, 65:689-701.
  10. Hou HL, Wan XR,  Xiang Y, Qi QW, Yang XY: Changes of clinical features in hydatidiform mole: analysis of 113 cases. J Reprod Med 2008, 53:629-633.
  11. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005;308:1592-94.
  12. Khong TY, De Wolf F: Inadequate material vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational age infants. Br Obstet Gynaecol 1986, 93:1049-1059.
  13. Hubel CA: Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med 1999, 222:222–235.
  14. Aquilina J, Harrington K: Pregnancy hypertension and uterine artery Doppler ultrasound. Curr Opin Obstet Gynecol 1996, 8:435–440.
  15. Burton GJ, Jauniaux E: Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig 2004 11:342– 352
  16. Plasencia W, Maiz N, Bonino S, Kaihura C, Nicolaides KH. Uterine artery Doppler at 11 + 0 to 13 + 6 weeks in the prediction of pre-eclampsia. Ultrasound Obstet.Gynecol. 2007;30:742-49.
  17. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrinol Metab 2003;88:2348–51.
  18. Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY. Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb Haemost 2005;94:1071–6.
  19. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS, Mallet AI, Poston L. A longitudinal study of biochemical variables in women at risk of preeclampsia. Am J Obstet Gynecol. 2002 Jul;187(1):127-36.
  20. Noori M, Donald AE, Angelakopoulou A, Hingorani AD, Williams DJ. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.Circulation. 2010 Aug 3;122(5):478-87
  21. Levine RJ, Maynard SE, Qian C, Lim HH, England LJ, Yu KF, Schisterman EF, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl JMed 2004; 350: 672–683.
  22. Widmer M, Villar J, Benigni A, Conde-Agudelo A, Karumanchi SA, Lindheimer M. Mapping the theories of preeclampsia and the role of angiogenic factors. Obstet Gynecol 2007; 109: 168–180.
  23. Parra, M., Rodrigo, R., Barja, P., Bosco, C.,Fernández, V., Muñoz, H., Soto-Chacón, E. Screeningtest for preeclampsia through assessment of uteroplacental blood flow and biochemical markers of oxidative stress and endothelial dysfunction. Am. J. Obstet. Gynecol. 2005;193:1486–191.
  24. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990;23:197-211.
  25. Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic, fibrinolytic and endothelial variables in normal pregnancies and pre-eclampsia. Br J Obstet Gynaecol 1994; 101:488-92.
  26. Brown NJ: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Ther Adv Cardiovasc Dis 2010 
  27. Ma Y, Ryu JS, Dulay A, Segal M, Guller S: Regulation of plasminogen activator inhibitor (PAI)-1 expression in a human trophoblast cell line by glucocorticoid (GC) and transforming growth factor (TGF)-beta.  Placenta 2002, 23:727-734
  28. Akolekar R, Cruz JD, Penco JM, Zhou Y, Nicolaides KH: Maternal Plasma Plasminogen Activator Inhibitor-2 at 11 to 13 Weeks of Gestation in Hypertensive Disorders of Pregnancy. Hypertens Pregnancy 2010.
  29. Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B: Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, pre-eclampsia and hydatidiform mole. Br J Obstet Gynaecol 1993, 100:370-374.
  30. Guller S, Ma Y, Malek A, Di Santo S, Schneider H: Differential release of plasminogen activator inhibitors (PAIs) during dual perfusion of human placenta: implications in preeclampsia. Placenta 2007, 28:278-85.
  31. Wikström AK, Nash P, Eriksson UJ, Olovsson MH: Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. Am J Obstet Gynecol 2009, 201:597-598. 
  32. Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am.J Physiol 1996;270:H411-H415.
  33. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 1999;274:25130-35.
  34. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658
  35. Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second-trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early-onset preeclampsia. Obstet Gynecol 2003;101:1266-1274
  36. Taylor RN, Grimwood J, Taylor RS, McMaster MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies. Am J Obstet Gynecol 2003;188:177-182
  37. Agarwal I, Karumanchi SA. Preeclampsia and the Anti-Angiogenic State. Pregnancy Hypertens. 2011 Jan 1;1(1):17-21.
  38. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med. 2006 Jan 26;8(3):1-20.
  39. Oliveira LG, Karumanchi A, Sass N. Preeclampsia: oxidative stress, inflammation and endotheial dysfunction. Rev Bras Ginecol Obstet. 2010 Dec;32(12):609-16.
  40. Wikstrom A-K, Larsson A, Eriksson U.J., Nash Peppi, Solveig Nordén-Lindeberg, and Olovsson M.  Placental Growth Factor and Soluble FMSLike Tyrosine Kinase-1 in Early-Onset and Late-Onset Preeclampsia. OBSTETRICS & GYNECOLOGY. VOL. 109, NO. 6, JUNE 2007
  41. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 1991;44: 139-43.
  42. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004;23:101–11.
  43. Li H, Gu B, Zhang Y, Lewis DF, Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 2005;26:210-7.
  44. Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997;18:657-65.